PUBLIC COMPANY
saveREGENERON PHARMACEUTICALS
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- phase2A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- phase3REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
- phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- phase2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- phase3A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- phase2A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
🐶 Hiring Signal
News
- Regeneron to challenge Ipsen as FDA clears bone disease drugPasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.biopharma_dive · 17h ago
- STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and moreA Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effortstat · 20h ago
- STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approvalA Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.stat · 1d ago
- 11 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.biospace · 1d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- EyePoint plummets on pivotal data for main drugThough its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.biopharma_dive · 3d ago
- EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD raceEyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.biospace · 3d ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 3d ago
- 7 companies hiring in North Carolina nowLooking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.biospace · 8d ago
comments(0)
5-min edit window · permanent after that